|
Priyanka's Biotech Briefing
AMO Pharma outlined a registrational study for AMO-02, Korea launched a next-generation hantavirus vaccine effort, and AbbVie reportedly moved toward a $10.9 billion Apogee deal.
The top 10 stories from Mon Jul 6, 2026 07:07 AM to Tue Jul 7, 2026 07:03 AM
Generated July 7, 2026 at 7:03 AM
|
|
|
#1 US FDA Readies Hemp Products Rule With Tighter THC Limits Imposed By Congress Approaching Published 2026-07-07 The FDA says its current enforcement discretion for hemp-containing supplements would not apply if Congress-imposed tighter THC limits take effect in November, making products unlawful for banks and insurers. Covered by: insights.citeline.com |
#2 Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy Published 2026-07-07 Vertex announced it will add an endocrine diseases business group by acquiring Crinetics in a deal reported as $10 billion. Covered by: insights.citeline.com, statnews.com, endpoints.news |
#3 Pipeline Watch: Eight Approvals And Fourteen Phase III Readouts Published 2026-07-06 Pipeline Watch reports a weekly snapshot of selected late-stage clinical trial events and approvals, including eight approvals and fourteen Phase III readouts announced by pharmaceutical and biotech companies. Covered by: insights.citeline.com |
#4 Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform Published 2026-07-06 Novartis said it will pay $1.1 billion upfront to acquire Myricx Bio, gaining its ADC payload platform, and expects to receive Myricx’s NMT assets as part of the deal. Covered by: endpoints.news, biotechtv.com |
#5 Beyond Rare: Nucleic Acid Therapeutics Are Targeting The Cardiovascular Mainstream Published 2026-07-06 Pharmaprojects data indicate more than 30 nucleic acid therapeutics are in clinical development for cardiovascular or cardiometabolic indications. Covered by: insights.citeline.com |
#6 New sa‑mRNA and LNP Platform to Support Korea’s Hantavirus Vaccine Initiative Published 2026-07-07 Korea University’s Vaccine Innovation Center will lead a government-supported project to develop next-generation hantavirus vaccines using self-amplifying mRNA and LNP platforms. Covered by: genengnews.com |
#7 Novartis’ ADC gambit & regulation as catalyst for U.K. biotech — a BioCentury podcast Published 2026-07-07 A BioCentury podcast discusses Novartis’ ADC strategy, U.K. biotech regulatory developments, and related U.S. FDA reform and China probe updates. Covered by: biocentury.com |
#8 AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada Published 2026-07-06 AMO Pharma plans a registrational study for AMO-02 in congenital myotonic dystrophy type 1, using hospitalization as the primary endpoint and multiple functional assessments as secondary endpoints, following regulatory feedback. Covered by: prnewswire.com, prnewswire.com |
#9 Roche aims to bolster breast cancer pipeline with early-stage Astex deal Published 2026-07-06 Roche’s subsidiary Genentech agreed with Astex, an Otsuka unit, on an early-stage breast cancer collaboration with a $25 million upfront payment. Covered by: endpoints.news |
#10 Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot Published 2026-07-06 AbbVie reportedly agreed to acquire Apogee Therapeutics for $10.9 billion after years of discussions, and the UK began a drug pricing pilot. Covered by: endpoints.news |
